After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | ...
ESMO: AstraZeneca faces challenge with FDA as Imfinzi, Lynparza miss survival goal in ovarian cancer
More than two years after a positive topline readout, AstraZeneca has to face the reality that a lack of an overall survival ...
In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...
Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early breast cancer in two pivotal clinical trials. | AstraZeneca and Daiichi ...
The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Fertility drugmaker EMD Serono, the U.S. arm of Merck KGaA, will offer its in vitro fertilization (IVF) treatments at a sharp discount on the government's DTC platform TrumpRx.
Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...
Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback